PD-L1 antagonist combination treatments
US10869924B2 · kind B2 · utility
5Cited by
43References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 15, 2016 |
| Grant date | Dec 22, 2020 |
| Priority date | — |
| Expiry date | Nov 5, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.